These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9831171)

  • 1. New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis.
    Breedveld F
    Eur Cytokine Netw; 1998 Sep; 9(3):233-8. PubMed ID: 9831171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNFalpha therapy for rheumatoid arthritis: an update.
    Taylor PC
    Intern Med; 2003 Jan; 42(1):15-20. PubMed ID: 12583612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of rheumatoid arthritis: targeting cytokines.
    Zwerina J; Redlich K; Schett G; Smolen JS
    Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Jones RE; Moreland LW
    Bull Rheum Dis; 1999; 48(3):1-4. PubMed ID: 10408141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of tumor necrosis factor for rheumatoid arthritis.
    Moreland LW
    J Rheumatol Suppl; 1999 May; 57():7-15. PubMed ID: 10328137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of tumor necrosis factor (TNF-alpha) in rheumatoid arthritis].
    Godyń-Swedzioł RM; Stańczyk J; Hilt J; Kowalski ML
    Przegl Lek; 2004; 61(2):90-3. PubMed ID: 15230148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT; Helfgott S
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M; Rødevand E; Skomsvoll JF
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
    Elliot MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katasikis P; Brennan FM; Bijl H; Ghrayeb J; Woody JN
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S92-S101. PubMed ID: 18240199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target.
    Boettger MK; Hensellek S; Richter F; Gajda M; Stöckigt R; von Banchet GS; Bräuer R; Schaible HG
    Arthritis Rheum; 2008 Aug; 58(8):2368-78. PubMed ID: 18668541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.
    van Vollenhoven RF; Klareskog L
    Arthritis Rheum; 2003 Jun; 48(6):1500-3. PubMed ID: 12794816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.